somatrogon sold brand name ngenla medication treatment growth hormone somatrogon glycosylated protein constructed human growth hormone small part human chorionic gonadotropin appended nterminal common side effects include reactions site injection headache somatrogon approved medical use australia november european union february united states june december committee medicinal products human use european medicines agency adopted positive opinion recommending granting marketing authorization medicinal product ngenla intended treatment growth hormone deficiency children adolescents three years applicant medicinal product pfizer europe somatrogon approved medical use european union february somatrogon international nonproprietary antagonists pegvisomant hormonal preparation article stub help wikipedia expanding httpsenwikipediaorgwikisomatrogon